The present disclosure provides methods of generating HLA class-I null cells that can be used for expression of exogenous HLA genes and presentation of antigens, such tumor neoantigens. Method for using HLA class-I null cells from selecting, stimulating and propagating immune effector cells are also provided.

Compositions and methods described in this document make use of macrophage derived engineered vesicles (MEV) having specificity for delivery to a target environment, for use in modifying macrophage phenotype and/or treating a condition. Further disclosed are MEV derived from a specific phenotype encapsulating a therapeutic agent for targeted therapeutic delivery.

The present invention relates to a method for inducing and proliferating target virus antigen-specific dual activated T cells, and can produce target virus antigen-specific dual activated T cells by treating monocytes, which are isolated from peripheral blood, with a cytokine and a virus antigen peptide mixture and culturing the same.

An interference image acquisition apparatus includes a light source, a beam splitter, a second reflection mirror, an imager, and a first reflection mirror. A cell is placed on one side of a transparent material, and the first reflection mirror is placed on the other side of the transparent material. In a two-beam interferometer, an optical path difference between an optical path length of a first light beam reflected by the first reflection mirror and an optical path length of a second light beam reflected by the second reflection mirror is set to a coherence length of light output from the light source or less. The imager acquires an interference image in a state in which the cell is placed at a position conjugate to an imaging plane in a first optical system between the imaging plane and the first reflection mirror.

The present disclosure provides methods for treating cancer and infectious disease using manufactured T cells or other cell types including antigen-presenting T cells, loaded, antigen-presenting T cells, sensitized, manufactured T cells and combinations thereof which can be co-administered with the manufactured T cells or without. Methods of treatment can include administration of pentostatin and cyclophosphamide followed by administration of T cells. The present disclosure also provides methods to produce antigen-presenting T cells from the manufactured T cells, load said antigen-presenting T cells and to sensitize the manufactured T cells using the loaded, antigen-presenting T cells. Methods of treatment using the antigen-presenting T cells and/or sensitized, manufactured T cells are also provided which can be performed in vivo or ex vivo.

The invention discloses a method for inhibiting the growth of cancer cells by use of an anti-cancer composition containing a conditioned cell culture medium from mesenchymal stem cells and cytokines. It comprises the steps of applying a composition with a conditioned cell culture medium from stem cells and at least one cytokine to cancer cells for growth inhibition of the cancer cells. The cell culture medium can be conditioned with Wharton's Jelly mesenchymal stem cells (WJMSCs) as an WJMSCs-conditoned cell culture medium, and the at least one cytokine is selected from a group consisting of bone morphogenetic protein-4, Dickkopf-related protein, Interferon-β and tumor necrosis factor-related apoptosis-inducing ligand.

The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-γ) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.

The present invention relates to the use of immunoregulatory macrophages for treating diseases that are associated with pathological changes of the blood vessels. The present invention particularly relates to the use of immunoregulatory macrophages for treating micro- and macroangiopathies of the lower limbs. The invention furthermore relates to the use of immunoregulatory macrophages for promoting tissue remodelling to facilitate wound healing. Pharmaceutical compositions for use in the recited treatments are also disclosed which comprise the immunoregulatory macrophages.

The present invention relates to a method of expanding and generating a population of cytokine-induced killer (CIK) cells from peripheral blood mononuclear cells comprising steps of a) separating the mononuclear cells from the peripheral blood; b) transferring the separated mononuclear cells into a culture medium; c) adding cytokines into the culture medium to induce expansion and generation of the CIK cells; and d) obtaining the expanded and generated population of CIK cells.

The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.